Neumora Therapeutics Inc. (NMRA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Neumora Therapeutics Inc. (NASDAQ: NMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.37 (-5.43% 1D, market cap $73.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMRA ranks #480 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NMRA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDF (Cardiff Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M) and GRML (Greenland Mines Ltd.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, NMRA leads on earnings multiple (N/A) while NMRA leads on capital efficiency (-35.0% ROIC).
Per NMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001885522), Neumora Therapeutics Inc. generated $0 in revenue, $236.9M in net income, and -$206.4M in free cash flow against $191.0M in total assets and $54.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.8 (OVERSOLD (<32))
Capital intensity & 0% operating margin leave 16 pts on the table
While NMRA currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.79) and Max Pain ($0.39) forces dealer call-delta covering toward $3.83.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Neumora Therapeutics Inc. (NMRA) dropped -5.43% to $0.37, trading at 2% of its 52-week range ($0.32 – $3.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
See today's largest US stock movers, including OPENW up 56.63%, MDXH down 60.55%, and other notable gainers and losers from the session.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NMRA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NMRA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Neumora Therapeutics Inc. (NMRA) ranks #480 by composite RQD confidence (42/100, grade D-) and #702 by equity capitalization ($73.0M). Within this direct 5-issuer industry benchmark cohort, NMRA leads on earnings valuation at N/A trailing P/E, while NMRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OKYO currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with NMRA at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NMRA
ACTIVE
Neumora Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -5.43% | $73.0M | Benchmark Subject |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | -2.46% | $70.9M | /crdf-vs-nmra → |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -10.89% | $70.3M | /grml-vs-nmra → |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -5.57% | $70.3M | /cgtx-vs-nmra → |
| OKYO OKYO Pharma Limited | D+ | 52/100 | — | — | — | -2.00% | $78.7M | /okyo-vs-nmra → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neumora Therapeutics Inc. (NMRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $236.9M, operating cash flow of -$206.4M, and free cash flow of -$206.4M (-12.8% YoY). On the balance sheet, NMRA closed FY2025 with $191.0M in total assets against $54.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $236.9M | -$206.4M | -$206.4M | $191.0M | $54.5M |
| FY2024 (FY) | 2024-12-31 | $0 | $243.8M | -$182.9M | -$182.9M | $317.0M | $0 |
| FY2023 (FY) | 2023-12-31 | $0 | -$235.9M | -$163.3M | -$163.3M | — | — |
As of 2026-11-02, Neumora Therapeutics Inc. (NASDAQ: NMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.37 (-5.43% 1D, market cap $73.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMRA ranks #480 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NMRA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDF (Cardiff Oncology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M) and GRML (Greenland Mines Ltd.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, NMRA leads on earnings multiple (N/A) while NMRA leads on capital efficiency (-35.0% ROIC).
Per NMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001885522), Neumora Therapeutics Inc. generated $0 in revenue, $236.9M in net income, and -$206.4M in free cash flow against $191.0M in total assets and $54.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NMRA last traded at $0.37 (-5.43% on volume of 1,107,541 shares), positioning the stock -53.16% below its 50-day simple moving average ($0.79) and -79.21% below its 200-day simple moving average ($1.78). Across its 52-week range of $0.32 to $3.65, NMRA sits at the 1.5% percentile with a 14-day RSI of 28.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).
Why NMRA Stock dropped -5.43% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, NMRA scores 42 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Implications for a prospective investor: The upside case depends on a turnaround in operating economics that the current ROIC and FCF figures do not yet show. The valuation tradeoff is that a $73.0M market capitalization against negative operating income of $-241.2M (FY 2025) leaves little margin for execution error. Balance-sheet strength is moderate rather than robust. This is an analytical framing of the rating, not personalized advice.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-241.2M | $236.9M | N/A | $-206.4M | $182.5M | $54.5M |
| FY 2024 | $0.0M | $-263.5M | $243.8M | N/A | $-182.9M | $142.1M | $0.0M |
| FY 2023 | $0.0M | $-252.1M | $-235.9M | N/A | $-163.3M | N/A | N/A |
Per the SEC financials, operating income is negative in each reported period, while reported net income is positive in FY 2025 and FY 2024 despite the operating losses. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9. Debt/Equity is 0.52 per the RQD rating, with cash rising from $142.1M (FY 2024) to $182.5M (FY 2025) alongside debt rising from $0.0M to $54.5M.
Per the recent news feed, the items are:
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Neumora Therapeutics Inc. (NMRA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Neumora Therapeutics Inc. (NMRA) market action, institutional positioning, and fundamental catalysts.
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Welcome to the NMRA (Neumora Therapeutics Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on NMRA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Neumora Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on NMRA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.37 (52-wk range $0.32 - $3.65), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).